secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akebia Therapeutics, Inc. (AKBA)
CIK:        0001517022
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001517022-25-000045
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akebia Q3 net income $0.5M; Vafseo revenue $14.3M; DaVita pilot ongoing
-----------------------------------------------------------------------

- Q3 total revenue $58.8M (up 57% YoY vs $37.4M); net income $0.5M vs net loss $20.0M in Q3 2024.
- Vafseo net product revenue $14.3M (launched Jan 2025); Auryxia net revenue $42.5M (up from $35.6M).
- DaVita operational pilot started Aug 18 over 100 clinics, expected to complete in Q4; target 275K patient access by year-end.
- FDA Type C meeting: no alignment on Phase 3 for non-dialysis; Akebia will not pursue broad label for non-dialysis.
- Cash $166.4M; company believes financed to achieve profitability under current operating plan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1517022/000151702225000045/0001517022-25-000045-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1517022/000151702225000045/akba-20251110.htm
  HTML page:      https://secwatch.observer/filing/0001517022-25-000045

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer